![Logo](/assets/logo-d3f1fdf60522f0983e71f9fcc720cb7da5b55c0b748ed5bded3d2fbf81387bf0.png)
CORD-19:cb16d307afaecebd683e6d74c8b501ed54b0c9a4 / 26101-26308
Annnotations
CORD-19-Sentences
{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T157","span":{"begin":0,"end":207},"obj":"Sentence"},{"id":"T7523","span":{"begin":0,"end":207},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition, compounds 82 and 83 (Fig. 6 ) were found to be prominent analogues with the lethality concentration (LC 50 ) values being 10.8 mg/mL and 14.5 mg/mL in sulforhodamine B (SRB) assay, respectively."}
CORD-19_Custom_license_subset
{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T157","span":{"begin":0,"end":207},"obj":"Sentence"}],"text":"In addition, compounds 82 and 83 (Fig. 6 ) were found to be prominent analogues with the lethality concentration (LC 50 ) values being 10.8 mg/mL and 14.5 mg/mL in sulforhodamine B (SRB) assay, respectively."}